High cholesterol secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 6: Line 6:


==Overview==
==Overview==
Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. However, some of the recent trial evidence suggested a more aggressive approach with a target LDL < 70 mg/dL. The NCEP recommendations are mentioned here, in addition to recent evidence.
Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence.


==Therapy goals==
==Therapy goals==
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL.  
NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients.
 
==Evidence incorporated in NCEP guidelines==
 
==Recent trials==


==Intensive versus moderate lowering of LDL==
==Intensive versus moderate lowering of LDL==

Revision as of 15:19, 12 September 2011


Template:Hypercholesterolemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-In-Chief: Kashish Goel, M.D.

Overview

Patients with [coronary heart disease] or newly diagnosed [acute coronary syndrome] are at a high risk of recurrent coronary events. In addition to modification of lifestyle factors, LDL lowering has been shown to reduce recurrent events, cardiovascular deaths and all-cause mortality in these patients. According to the [NCEP ATP III guidelines], LDL cholesterol of < 100 mg/dL is the goal in patients with CHD and CHD risk equivalents. The NCEP recommendations are mentioned here, in addition to recent evidence.

Therapy goals

NCEP ATP III guidelines recommended a LDL goal < 100 mg/dL for CHD or CHD risk equivalents, however drug therapy was considered optional between a LDL of 100 to <130 mg/dL. An update by the NCEP committee in 2004 based on new trial data recommended starting drug therapy simultaneously with therapeutic lifestyle changes in CHD patients with LDL < 100 mg/dL. An optional goal of LDL < 70 mg/dL was recommended in high risk patients.

Intensive versus moderate lowering of LDL